Warning: full spoilers for The Batman ahead! Now that audiences have seen The Batman, we’re left to pore over Matt Reeves’ three-hour epic that saw Robert Pattinson’s Dark Knight take on Paul Dano’s ...

Who Is the Villain in The Batman: Part II? While we might not know who the villain is just yet, we have some ideas—and it all stems from director Matt Reeves himself. In a red carpet interview from ...

We finally have our first look at “The Batman: Part II.” Matt Reeves revealed camera test photos for “The Batman: Part II” on Thursday, showing the first images from the long-awaited sequel starring ...

The Caped Crusader returns next year with Lego Batman: Legacy of the Dark Knight launching on PlayStation 5, Switch 2, Xbox Series X|S, and PC on May 29, 2026. This all-new Lego Batman title looks to ...

The Caped Crusader has been a TV stalwart, but the big screen is the home of his most legendary adventures. Superhero movies have ebbed and flowed in terms of popularity since Christopher Reeve first ...

Lucas Kloberdanz-Dyck is a writer for Collider. He grew up creating lists, stories, and worlds, which led to his love of anime and video games. He attended Sheridan College where he earned an Honours ...

Unique programmability lets you re-create a professional audiogram in the app. Quite comfortable despite large size. Excellent as streaming receivers. Moderate trouble with overall level and echoes in ...

Co-created by 'Batman: The Animated Series' producer Bruce Timm, this throwback to the hero's gritty early days is a blast (*) Harley and Gotham cop Renee Montoya (Michelle Bonilla) also appear to be ...

“Batman: Caped Crusader,” a new animated series, is not concerned with making its hero likable — either to the citizens of Gotham or to its audience. By Dave Itzkoff The story of Batman has been told ...

Everyone is still mourning the passing of Kevin Conroy, the eternal voice of animated Batman across dozens of projects and multiple decades. The actor died in 2022 from cancer. However, as voice ...

Switzerland’s Melodia Therapeutics has signed a $275 million biobucks deal to get its hands on Alivexis’ preclinical cathepsin C inhibitor. Melodia said it will “rapidly initiate” IND-enabling ...